Navigation Links
PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
Date:9/15/2008

ecombinant protective antigen (rPA) anthrax vaccine being developed for administration by intramuscular injection. Phase I and Phase II clinical trials involving more than 700 healthy human subjects have been completed and showed that SparVax(TM) appears to be well tolerated and induces an immune response in humans. These studies suggest that three doses of SparVax(TM), administered several weeks apart should be sufficient to induce protective immunity. In preclinical studies SparVax(TM) has also demonstrated the capability to protect rabbits and non-human primates against a lethal aerosol spore challenge of the anthrax Ames strain.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

-- SparVax(TM) - a second generation recombinant protective antigen (rPA)

anthrax vaccine

-- Third generation rPA anthrax vaccine

-- Valortim(R) - a fully human monoclonal antibody for the prevention and

treatment of anthrax infection

-- Protexia(R) - a novel bioscavenger for the prevention and treatment of

morbidity and mortality associated with exposure to chemical nerve

agents

-- RypVax(TM) - a recombinant dual antigen vaccine for plague

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potentia
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Mass. , April 16, 2015  EMD ... Merck KGaA, Darmstadt, Germany , ... Vice President, Head of Global Clinical Development.  Dr. ... expertise, including experience in Oncology and Immunology. She ... ability, having served as a Vice President in ...
(Date:4/16/2015)... and MENLO PARK, Calif. ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical ... in new orphan drug indications, today announced that the ... as a clinical trial site for the ongoing, multicenter ... glioblastoma multiforme (GBM), the most common and deadly form ...
(Date:4/16/2015)... , April 16, 2015  Northwest Biotherapeutics, Inc. ... company developing non-toxic DCVax® personalized immune therapies for ... in the Loncar Cancer Immunotherapy Index (LCINDX), a ... track the immunotherapy field within the biotechnology space.  ... "the top 25 companies" in the immunotherapy space, ...
(Date:4/16/2015)... Modality Solutions, a company that delivers ... industries, is pleased to announce its President, Gary ... Cold Chain IQ - Temperature Control Logistics and ... Global Cold Chain Connections, is dedicated to sharing ... pharmaceutical and healthcare supply chains. , Cold ...
Breaking Biology Technology:Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3
... ... delivers Market Leading Economies to Reduce Synthesis Costs and Increase Yields , ... Oceanside, CA (PRWEB) April 26, ... and the market leader in solid support for oligonucleotide synthesis, will be launching its ...
... computers are static. In our brains, information processing ... international research team from Japan and Michigan Technological ... evolution in an organic molecular layer that can ... a brain-like "evolutionary circuit" has been realized. ...
... SHANGHAI , April 23 /PRNewswire-Asia/ -- ... that it filed its annual report on Form 20-F for,the ... and Exchange Commission.,The annual report can be accessed on WuXi ... WuXi,PharmaTech will provide a hard copy of its annual report ...
Cached Biology Technology:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Launch of NittoPhaseHL – High Loaded Solid Support for Oligonucleotide Synthesis 2Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Launch of NittoPhaseHL – High Loaded Solid Support for Oligonucleotide Synthesis 3Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Launch of NittoPhaseHL – High Loaded Solid Support for Oligonucleotide Synthesis 4WuXi PharmaTech Files 2009 Annual Report on Form 20-F 2
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
Breaking Biology News(10 mins):higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... group of chemical compounds used by a species of ... promising antimalarial properties for humans. The compounds are part ... to battle enemies and that may provide a ... novel analytical process, researchers at the Georgia Institute of ...
... successfully being used in clinical trials to treat patients with ... die, it also forces them to release pro-inflammatory chemokines and ... attack the disease. New research published by BioMed Central,s open ... infected cancer cells secrete proteins which, even when isolated, result ...
... Variations in skin color provide one of the best ... body and should be used to teach evolution in schools, ... level of interest in skin color and for teachers, that ... Nina Jablonski, professor and head, Department of Anthropology, Penn State. ...
Cached Biology News:Antifungal compound found on tropical seaweed has promising antimalarial properties 2Antifungal compound found on tropical seaweed has promising antimalarial properties 3Antifungal compound found on tropical seaweed has promising antimalarial properties 4Skin color: Handy tool for teaching evolution 2Skin color: Handy tool for teaching evolution 3
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
Biology Products: